Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous
system characterized by demyelination and axonal loss. The etiology of MS is unknown; …

The treatment era for multiple sclerosis began in 1993 with the approval of the first disease‐
modifying therapy. This changed the management of multiple sclerosis from treating acute …

In de novo-treated patients, the injectables, IFN-β and glatiramer acetate, will to a great
extent be replaced by the new orals, dimethyl fumarate and teriflunomide. However, patients …

Although the earliest recorded description of multiple sclerosis (MS) dates back to the 14 th
century, it was not until the latter years of the 20 th that treatments for this disabling condition …

The past few years have witnessed major advancements in our ability to diagnose multiple
sclerosis (MS) and begin treatments that can favorably modify the course of the disease. In …

Current therapeutic landscape in multiple sclerosis: an evol... : Current Opinion in
Neurology Current therapeutic landscape in multiple sclerosis: an evolving treatment …

Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system
determined by a presumed autoimmune process mainly directed against myelin …

Multiple sclerosis (MS) is a chronic inflammatory demyelinating central nervous system
disease that typically strikes young adults, especially women. The pathobiology of MS …

The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …

The range of symptoms which occur in multiple sclerosis (MS) can have disabling functional
consequences for patients and lead to significant reductions in their quality of life. MS …